Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Chubb
Baxter
Teva
Healthtrust
Fish and Richardson
Moodys
Boehringer Ingelheim
Dow

Generated: May 23, 2018

DrugPatentWatch Database Preview

PAREDRINE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Paredrine, and when can generic versions of Paredrine launch?

Paredrine is a drug marketed by Pharmics and is included in one NDA.

The generic ingredient in PAREDRINE is hydroxyamphetamine hydrobromide. There are two drug master file entries for this compound. Additional details are available on the hydroxyamphetamine hydrobromide profile page.
Summary for PAREDRINE
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 8
Patent Applications: 46
DailyMed Link:PAREDRINE at DailyMed
Drug patent expirations by year for PAREDRINE
Synonyms for PAREDRINE
.beta.-(p-Hydroxyphenyl)isopropylamine hydrobromide
(+-)-p-(2-Aminopropyl)phenol hydrobromide
(+-)-Paredrine hydrobromide
(+)-4-Hydroxyamphetamine hydrobromide
(+/-)-4-Hydroxyamphetamine hydrobromide
1-p-Hydroxyphenyl-2-aminopropane hydrobromide
103-86-6 (Parent)
140-36-3
2-Amino-1-(4-hydroxyphenyl)propane hydrobromide
3-(p-Hydroxyphenyl)-2-aminopropane hydrobromide
306-21-8
4-(2-aminopropyl)ph |nol bromhydrate
4-(2-Aminopropyl)phenol hydrobromide
AC1L1SWY
AC1Q23OC
beta-(p-Hydroxyphenyl)isopropylamine hydrobromide
C9H13NO.HBr
CAS-306-21-8
CCG-213716
CHEMBL1200705
cid_9377
component of Paredrine
CTK4G5491
D04473
D0W1RY
dl-p-(2-Aminopropyl)phenol hydrobromide
DSSTox_CID_25961
DSSTox_GSID_45961
DSSTox_RID_81257
DTXSID0045961
EINECS 206-181-4
HMS1923C15
Hydroxyamfetamin hydrobromid
hydroxyamfetamine hydrobromide
HYDROXYAMPHETAMINE HYDROBROMIDE
Hydroxyamphetamine hydrobromide (USP)
Hydroxyamphetamine hydrobromide [USP]
HYDROXYAMPHETAMINEHYDROBROMIDE
Hyroxyamfetamine hydrobromide
LS-103951
LS-103952
MLS002320672
MLS002320674
Mycadrine
NCGC00095233-01
NCGC00095233-02
NSC 61065
NSC-61065
NSC-760066
NSC61065
NSC760066
OXAMPHETAMINE HYDROBROMIDE
p-(2-Aminopropyl)phenol hydrobromide
p-(2-Aminopropyl)phenyl hydrobromide
p-Hydroxyamphetamine hydrobromide
Paredrine (TN)
Paredrine hydrobromide
Pharmakon1600-00211425
Phenol, 4-(2-aminopropyl)-, hydrobromide
Phenol, hydrobromide
Phenol, p-(2-aminopropyl)-, hydrobromide
Phenol, p-(2-aminopropyl)-, hydrobromide, (+-)-
Phenol,4-(2-aminopropyl)-, hydrobromide (1:1)
Predrolon
rac. 4-hydroxy-alpha-methylphenethylamine hydrobromide
RZCJLMTXBMNRAD-UHFFFAOYSA-N
SCHEMBL221647
SMR001338818
SMR001338820
SPECTRUM211425
Tox21_111487
WLN: ZY1&1R DQ &EH

US Patents and Regulatory Information for PAREDRINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmics PAREDRINE hydroxyamphetamine hydrobromide SOLUTION/DROPS;OPHTHALMIC 000004-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Express Scripts
Queensland Health
UBS
Moodys
Baxter
Citi
Healthtrust
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.